Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.40 |
| ▸ | HTR1D | P28221 | 6/20 | 0.40 |
| ▸ | HTR1B | P28222 | 6/20 | 0.40 |
| ▸ | HTR1A | P08908 | 5/20 | 0.40 |
| ▸ | HTR7 | P34969 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2992803 | 1.00 | HTR6 (0.40) | HTR6HTR1DHTR1BHTR1AHTR7 | |
| Trifluoroacetic Acid SCHEMBL2996830 | 0.93 | PIK3CA (0.36) | HTR6HTR1DHTR1BHTR1AHTR7 | |
| Trifluoroacetic Acid SCHEMBL2996823 | 0.93 | PIK3CA (0.36) | HTR6HTR1DHTR1BHTR1AHTR7 | |
| Trifluoroacetic Acid SCHEMBL2990510 | 0.88 | ENPP2 (0.40) | HTR6HTR1DHTR1BHTR1AHTR7 | |
| Trifluoroacetic Acid SCHEMBL2990505 | 0.88 | ENPP2 (0.40) | HTR6HTR1DHTR1BHTR1AHTR7 | |
| SCHEMBL2992807 | 0.83 | ENPP2 (0.38) | HTR6HTR1DHTR1BHTR1AHTR7 | |
| SCHEMBL2990909 | 0.81 | MAPK14 (0.43) | HTR6HTR1DHTR1BHTR1AHTR7 | |
| SCHEMBL2990912 | 0.81 | MAPK14 (0.43) | HTR6HTR1DHTR1BHTR1AHTR7 | |
| Trifluoroacetic Acid SCHEMBL2996289 | 0.81 | BRAF (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL2996297 | 0.81 | BRAF (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214455-A1 | Novel Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | claimed |
| EP-1879563-A4 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-07-16 | — | — | EP | claimed |
| EP-1879563-A2 | NOVEL CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-01-23 | — | — | EP | claimed |
| WO-2006132739-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | claimed |
| US-20100184774-A1 | METHODS OF TREATMENT | SMITHKLINE BEECHAM CORPORATION | 2010-07-22 | — | — | US | disclosed |
| US-20080214455-A1 | Novel Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| EP-1879563-A4 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1879563-A2 | NOVEL CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006132739-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214455-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | HTR6 3461/4885HTR1D 4264/4885HTR1B 4230/4885 |
| US-20100184774-A1 | METHODS OF TREATMENT | OPRL1, BRCA1, PKD1 | HTR6 53/4885HTR1D 271/4885HTR1B 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.